A vlog update on advanced prostate cancer from the AUA 2011 meeting
After attending numerous basic research and clinical updates at the American Urologic Association (AUA) annual meeting in Washington DC, it is clear that the new and emerging therapies are not going to stop at the three grand crus from 2010.
Recently, abiraterone acetate (Zytiga) was approved, but there are a number of critical issues that need to considered, including:
- Sequencing
- Combinations
- Cost
- Patient selection
As we learn more about the molecular mechanisms behind resistance to androgen receptor signaling (up and downstream) and new targets emerge, so it may be possible to improve patient outcomes in castration-resitant prostate cancer.
Here’s a short video update of what I thought was interesting here at the conference:
3 Responses to “A vlog update on advanced prostate cancer from the AUA 2011 meeting”
me gustaria que me indicaras como hacer para conseguir Xytiga, somos de argentina pero vamos a EE.UU en algunas oportunidades , si me puedes ayudar te lo agradeceria
Saludos
Anibal
[…] of you will remember the video discussion from the American Urological Association meeting earlier this year, where we highlighted the […]
[…] 2011 Prostate Cancer News Posted on May 16, 2011 by Daedalus Sally Church on Pharma Strategy Blog has published a video blog (vlog) post on what’s hot in Prostate Cancer at the 2011 AUA (American […]
Comments are closed.